Pioneering research by biomedical scientists at Harvard Medical School into a novel class of pro-resolving mediators - designated Resolvins - has shown these to be potent agonists of inflammation resolution and tissue repair and - critically - these can be delivered therapeutically to counteract an overactive inflammatory response without compromising immune function. Anchored in these findings, Thetis Pharmaceuticals is working on development of a technology platform - designated HEALER⢠- designed to enable the development of Resolvins as new molecular entities with enhanced stability and bioavailability, overcoming key hurdles that have historically limited their development as pharmaceutical drugs. Speifically, Thetis is leveraging these findings to develop a pipeline of drug candidates for cancers and autoimmune diseases. The firm's lead candidate is a novel Resolvin E1 small molecule therapy (TP-317) addressing solid tumor cancers and inflammatory bowel disease (IBD) while also offering a differentiated therapeutic strategy that harnesses natural resolution mechanisms without suppressing the immune system. Based on Phase 1 clinical trials demonstrating the favorable safety and tolerability of orally administered RvE1 in healthy volunteers, Thetis management plan to advance TP-317 rapidly into clinical development
